

# SAVE THE DATE

**16 – 17 May 2014**

Mercure Toulouse Compans Caffarelli,  
Toulouse, France

Endocrinology  
**FIRST**



A **Pfizer** Programme

## Prader Willi Syndrome: *Translating knowledge into future care*

### Goals/Objectives

The aim of this expert meeting is to review the progress we have made in understanding the genetics, metabolic and behavioural aspects of PWS and translate this knowledge into management of patients.

### Scientific Planning Committee

**Prof Maithé Tauber**  
(Chair)  
Hôpital des Enfants  
and Paul Sabatier  
Université  
Toulouse, France

**Prof Véronique  
Beauloye**  
Cliniques St-Luc  
Catholic University  
of Louvain  
Brussels, Belgium

**Prof Tony Goldstone**  
Hammersmith Hospital  
Imperial College  
London, UK

**Prof Berthold Hauffa**  
University Children's  
Hospital,  
Essen, Germany

**Prof Anita  
Hokken-Koelega**  
Erasmus University  
Medical Center  
Rotterdam, Netherlands

**Prof Jennifer Miller**  
University of Florida  
College of Medicine  
Florida, US

**Prof Annick Vogels**  
University Hospitals  
Leuven  
Leuven, Belgium

### Agenda

#### Friday 16 May 2014

Time	Topic	Chair / Co-chair	Speaker
8:20 – 8:30	Welcome and Program Overview		Maithé Tauber (France)
8:30 – 9:00	PWS in 2014		Maithé Tauber (France)
<b>Session 1: Eating behaviour and beyond</b>			
9:00 – 10:30		Jennifer Miller/ Jean-Paul Thissen	
	Hyperphagia in PWS is not just the hypothalamus		Tony Goldstone (UK)
	Does acylated and non acylated Ghrelin matter in PWS?		Renske Kuppens (Netherlands)
	Does Oxytocin offer hope for PWS?		Maithé Tauber (France)
	What do infant studies tell us about hyperphagia onset in PWS?		Veronique Beauloye (Belgium)
	Hot Topic		
10:20 – 11:00	Break		
<b>Session 2: Metabolic aspects</b>			
11:00 – 12:30		Veronique Beauloye/ Anita Hokken	
	Mitochondrial dysfunction in white adipose tissue and obesity		Martin Wabitsch (Germany)
	Should we treat obesity with targeting brown/beige adipocyte?		TBC
	Adipose tissue in children and adults		Christine Poitou (France)
	Hot Topic		
12:30 – 13:30	Lunch		

Time	Topic	Chair/Co-chair	Speaker
<b>Session 3: Behavioural problems and psychiatric disorders</b>			
13:30 – 15:05		Annick Vogels/ Tony Holland	
	Behavioural features in PWS		Denise Thuilleaux ( <i>France</i> )
	Psychiatric features in PWS		Annick Vogels ( <i>Belgium</i> )
	Practical consequences of emotional, social and cognitive impairments in children?		Sinddie Lo ( <i>Netherlands</i> )
	Practical consequences of emotional, social and cognitive impairments in adults?		Johan Chevalere ( <i>France</i> )
	Hot Topic		
15:05 – 15:30	Break		
<b>Session 4: Growth hormone in paediatrics and adolescents</b>			
16:00 – 17:30		Maithe Tauber/ Alessandro Salvatoni	
	How has long-term GH treatment changed the PWS phenotype in children?		Anita Hokken ( <i>Netherlands</i> )
	What is the right age to start GH in childhood?		Veronique Beauloye ( <i>Belgium</i> ) Gweanelle Diene ( <i>France</i> )
	Is monitoring IGF1 levels of value in GH treatment in children? (debate)		<b>Pro:</b> Jennifer Miller ( <i>US</i> ) <b>Against:</b> Berthold Hauffa ( <i>Germany</i> )
	What do we do with GH in transition?		Alessandro Salvatoni ( <i>Italy</i> )
	Hot Topic		
17:30 – 18:30	Poster session		

### Saturday 17 May 2014

Time	Topic	Chair/Co-chair	Speaker
<b>Session 5: Genetics to patients</b>			
8:30 – 10:30		Tony Goldstone/ Francoise Muscatelli	
	General overview of genetics of PWS (MKRN3, future)		Bernhard Horsthemke ( <i>Germany</i> )
	Learning from Mice (models) and Men: 2 Case presentations SNORD 116		Jerome Cavaillé ( <i>France</i> ) Francoise Lorenzini ( <i>France</i> )
	Magel2/NDN		Francoise Muscatelli ( <i>France</i> ) Christian Patrick Schaaf ( <i>US</i> )
	How to define, explore and manage a PWS-like patient: criteria, diagnostic steps and care. Round table discussion		Maithé Tauber ( <i>France</i> ), Jennifer Miller ( <i>US</i> ), Berthold Hauffa ( <i>Germany</i> ) and Bernhard Horsthemke ( <i>Germany</i> )
10:30 – 11:00	Break		
<b>Session 6: Adults</b>			
11:00 – 12:30		Berthold Hauffa/ Graziano Grugni	
	How to manage puberty in PWS and sex steroid replacement?		Antonino Crino ( <i>Italy</i> )
	What are the benefits of GH in adult PWS including bone health?		Charlotte Hoybye ( <i>Sweden</i> )
	How to assess and improve QoL in adolescents and adult PWS?		Tony Holland ( <i>UK</i> )
	Hot Topic		
12:45 – 13:00	Closing Remarks		Maithé Tauber ( <i>France</i> )
13:00	Lunch and departures		

Pfizer Ltd has initiated and sponsored the “Prader Willi Syndrome: Translating knowledge into future care” meeting. The Scientific Planning Committee (SPC) of this event is comprised of specialists who provide scientific and planning oversight for the overall programme and content. Its members are recognised experts in the field of PWS and they receive an honorarium from Pfizer Ltd. for this work. The communications of this meeting represent the scientific opinions of the individual presenters and may not necessarily represent the opinions of Pfizer Ltd. or any of its subsidiaries, partners or employees.

Financial support provided  
by Pfizer Ltd.



CME accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) has been applied for.

Date of preparation: January 2014. EBT/GEN/14/06